Previous Close | 17.44 |
Open | 17.05 |
Bid | 16.76 x 3200 |
Ask | 17.15 x 1100 |
Day's Range | 16.26 - 17.33 |
52 Week Range | 7.26 - 21.39 |
Volume | |
Avg. Volume | 2,950,324 |
Market Cap | 2.153B |
Beta (5Y Monthly) | 1.29 |
PE Ratio (TTM) | 20.76 |
EPS (TTM) | 0.82 |
Earnings Date | Nov 02, 2022 - Nov 07, 2022 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 25.50 |
Subscribe to Yahoo Finance Plus to view Fair Value for DVAX
The average of price targets set by Wall Street analysts indicates a potential upside of 92.2% in Dynavax Technologies (DVAX). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
When a stock breaks out above the 20-day simple moving average, good things could be on the horizon. How should investors react?
Before we begin, I advise you that we will be making forward-looking statements today based on our current expectations and beliefs, including, but not limited to potential market sizes and market share; market trends; impact of ACIP recommendations and timing of such impact; financial guidance and trends, including revenue, profitability, and sufficiency of current capitalization; timing and results of clinical trial starts and data readouts and potential future uses of CpG 1018 adjuvant. Joining me on the call today are Ryan Spencer, chief executive officer; Donn Casale, senior vice president of commercial; Rob Janssen, chief medical officer; and Kelly MacDonald, chief financial officer.